Despite Controversies, China Follows Same Bioethical Regulations As The West
Junjiu Huang and his research team at Sun Yat-sen University in Guangzhou, China, used CRISPR-Cas9 to edit the genome of non-viable human embryos. The publication of that study generated a huge amount of controversy, with an article in the New York Times claiming: “medical researchers in China are stepping over ethical boundaries long accepted in the West.”
This view assumes that there is a substantial difference in standards between Western countries and their non-Western competitors. The Chinese research team were perceived to have succeeded in their scientific endeavor primarily because China was assumed to have little or no regulatory control over human embryo research.
This view assumes that there is a substantial difference in standards between Western countries and their non-Western competitors. The Chinese research team were perceived to have succeeded in their scientific endeavor primarily because China was assumed to have little or no regulatory control over human embryo research.